ABSTRACT [First-level Header] Objective: To describe rank reversal as a source of inconsistent interpretation intrinsic to indirect comparison (Bucher et al., 1997) of treatments and to propose best practice.
Introduction
[First-level Header]
When a direct comparison of two or more treatments within the same study is not possible, researchers must instead make indirect comparisons of those treatments across different trials. Bucher and colleagues [1] first showed how to conduct an indirect comparison meta-analysis. Under the assumption that the relative efficacy of the treatments are consistent for patients in the different trials [2, 3] , Bucher and colleagues [1] show that the log odds of the adjusted indirect comparison of two treatments (each compared to a placebo or common control treatment) is a simple function-the difference in the log odds ratio of each treatment compared to its control. Their basic method has proved quite influential. While others have expanded upon it [3, 4, 5] , the basic model has been used in numerous meta-analyses.
Although Bucher and colleagues present their model using odds ratios, they also assert that the "method could be equally applied to estimates of relative risk" (Bucher et al., 1997, p. 684 ). Song and colleagues (2000, p. 489) state that Bucher's method of adjusted indirect comparison "may also be used when the relative efficacy is measured by risk ratio or by risk difference." Indeed, there are a few studies that have modified the formulas appropriately and used either the risk ratio or the risk difference instead of the more common odds ratio (e.g., [6] ).
The central point of this paper is that when indirectly comparing two or more treatments, the choice of how to express results may directly affect the conclusion. In other words, when sorting treatments by effect size (which we refer to as ranking), the choice between risk ratio, risk difference, and odds ratio matters. We describe these three measures and show when indirect comparisons using any of the measures will be different from the others. We illustrate our results with intuition, examples, graphs, and mathematical proofs. We are unaware of previous description of this phenomenon, which we call rank reversal.
We explain our main points in the context of an indirect comparison meta-analysis, whereby two treatments (let's call them A and B) are each compared to a control (called C) in separate studies. The goal is to use the information in these two separate studies to indirectly compare treatments A and B, and thereby rank their effectiveness. For example, compared to a placebo, is the desirable outcome more likely when a patient takes drug A rather than drug B? The answer to this question is important for both practice and policy. As we explain, answering this question is not always straightforward. When compared to their respective placebos, drug A may be preferred to drug B when measured by a risk ratio, but drug B may be preferred to drug A when measured by an odds ratio, even though both odds ratio and risk ratio are measures of relative effectiveness.
We prove that rankings are not always consistent across these risk measures, describe under what circumstances the rankings are the same or different, explain how uncertainty affects the main results, introduce software that can help identify problems, discuss implications, and recommend best practice for research and policy. When the study design is such that the results could be expressed in terms of either risk ratios or odds ratios, the burden is on the researcher to specify a conceptual framework to make that choice.
Methods [First-level Header]
Consider pairs of probabilities   0 1 , R R , with 0 R referring to the baseline (control) risk and 1 R to the risk if treated. These risks are defined as probabilities of an event during a specified period of time [7] , and so are bounded by zero and one. For any pair of probabilities   0 1 , R R we can define the risk ratio, risk difference, and odds ratio with 0 R as the reference.
We state two proofs, and direct the reader to the Appendix for the details of those proofs. First, within a single study, where baseline risk is the same, treatment alternatives will have the same ranking regardless of the risk measure used. In other words, all three risk measures are strictly monotonic in changes in risk to the treatment group   
The intuition of the first proof is shown graphically by moving due north of (0.4, 0.6) in Figure 1 . R , the rankings of any two treatments will be the same for RR, RD, and OR.
The situation changes when comparing points that do not share the same baseline risk 0 R . To make our point simpler, we have redrawn Figure 1 without the RD isoquants, to focus only on RR and OR (see Figure 2 ). We can compare any point to (0.4, 0.6) and ask: Is one risk ratio higher than the other? Do the risk ratios and odds ratios have the same ranking? If the other point lies to the northwest of (0.4, 0.6) in the area marked A, then it will have higher values of both RR and OR. If it lies to the southeast (large area marked D) then it will have lower values of both RR and OR. In these cases, both RR and OR rank these points the same; there is no rank reversal.
The interesting cases lie to the southwest and to the northeast in the areas marked B and C. For example, take the point (0.6, 0.8) in area C. This point has a lower RR than (0.4, 0.6) (RR = 1.33 instead of 1.5); as such, it lies below the RR isoquant. But it has a higher OR than the point (0.4, 0.6) and lies above the OR isoquant. Therefore, (0.6, 0.8) has a different ranking compared to (0.4, 0.6) when using
We show two other examples, again focusing on just RR and OR. Both examples lie along the same OR isoquant, so only the RR is changing. One has a tiny area B and a relatively large area C (see Fig. 3 ).
The other is the opposite, with area B being much larger than area C (see Fig. 4 ). These examples show that location on the graph affects the probability that other points in the vicinity will have rank reversal problems. When both risks are small the chance that the OR of another point nearby exceeds the RR is almost zero.
Finally, to bring RD back into the picture we return to Figure 1 which has all three isoquants. In this In summary, after drawing a point   0 1 , R R on the graph and the corresponding three isoquants, then only the points entirely above all three isoquants or entirely below all three have the same ranking on all measures. While the area of the graph with the same ranking is always in the majority, in our experience reading the literature, studies that are compared to each other often lie broadly along the southwest to northeast corridor, making the choice of measure (RR, RD, or OR) important in the final comparison (e.g., [9] Total area = 1 ************************************************ ************************************************ All same 0.9095
RD different 0.0239 ************************************************ In this example, the two areas where all three measures agree on the ranking (areas A and G) together comprise 90 percent of the area of the unit square (see Fig. 1 ). Measuring risk using an odds ratio generates a ranking different from the other two measures in region G, which has an area of 0.0239.
However, areas B and F do not exist for this risk pair-it is impossible for another point to have a lower OR than (0.4, 0.6) while simultaneously having a higher RR and RD.
Best Practice Recommendations [First-level Header]
Our results lead to several recommendations for best practice when making indirect comparisons. First, given the conceptual framework and study design, decide which measure is most appropriate for the research. There is an extensive literature on the differences between RR, RD, and OR (for guidance, see textbooks by [7, 10, 11, 12] and articles [13, 14, 15] ). For some study designs, such as case-control studies, only the odds ratio is possible. Attention should also be paid to clarity of presentation of results [16, 17, 18, 19, 20, 21, 22] . As a default, we recommend using one of the risk measures instead of the odds ratio, unless there is a conceptual justification favoring the odds ratio. Second, for studies that have a study design that allows appropriate reporting of either risk ratios or odds ratios [23] , show whether the different measures would lead to the same or different rankings. Either the result is robust across measures or the authors should acknowledge that other measures would lead to different conclusions and discuss this finding in light of the conceptual model.
Conclusions [First-level Header]
The federal government is currently advocating head-to-head clinical trials, with several drugs being tested at once against the same placebo. This design both avoids the problem of comparing treatments to different placebos, and also will increase dramatically the number of indirect comparisons being conducted in clinical research. While the methods of Bucher and colleagues [1] will inform the analysis of these trials, the results of this study demonstrate the importance of the choice of risk measure when conducting indirect comparisons. This study has several important conclusions. First, we have two main mathematical results. The first is that if comparisons are made within the same study to the same control then the three measures will always have the same ranking. The more interesting result is that the choice of risk measure matters when making indirect comparisons of treatments with different baseline risks.
This result holds regardless of whether or not there is uncertainty about the risks.
Our results have strong policy implications. Because researchers often choose a risk measure out of convenience or habit, policy decisions based on treatment ranking may be driven in part by these 
In contrast to the previous result, the sign of the total differentiation depends on dR dR is greater than one but less than 1 0
